See more : Pantheon Infrastructure PLC (PINT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Tenaya Therapeutics, Inc. (TNYA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tenaya Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SenseTime Group Inc. (0020.HK) Income Statement Analysis – Financial Results
- China Huajun Group Limited (0377.HK) Income Statement Analysis – Financial Results
- Rishabh Instruments Limited (RISHABH.NS) Income Statement Analysis – Financial Results
- Healthcare Capital Corp. (HCCCU) Income Statement Analysis – Financial Results
- Pegatron Corporation (4938.TW) Income Statement Analysis – Financial Results
Tenaya Therapeutics, Inc. (TNYA)
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross Profit | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.04M | 94.54M | 54.39M | 31.10M | 23.15M |
| General & Administrative | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Other Expenses | 0.00 | 2.00K | -23.00K | 430.00K | 1.03M |
| Operating Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Cost & Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Interest Income | 7.06M | 1.95M | 108.00K | 87.00K | 453.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| EBITDA | -122.51M | -114.95M | -68.70M | -36.43M | -25.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -131.19M | -125.62M | -72.81M | -38.91M | -27.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.11M | 1.96M | 85.00K | 517.00K | 1.48M |
| Income Before Tax | -124.08M | -123.67M | -72.72M | -38.40M | -26.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.96K | -3.07M | -87.00K | -453.00K |
| Net Income | -124.08M | -123.66M | -69.65M | -38.31M | -25.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| Weighted Avg Shares Out | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
| Weighted Avg Shares Out (Dil) | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
Tenaya Therapeutics Announces Pricing of Underwritten Offering
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Source: https://incomestatements.info
Category: Stock Reports